46 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years https://www.fool.com/investing/2024/01/28/a-bull-market-is-here-2-stocks-to-buy-and-hold-for/?source=iedfolrf0000001 Jan 28, 2024 - These companies can perform well through this bull run and beyond.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release https://www.zacks.com/stock/news/2215849/merck-mrk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215849 Jan 25, 2024 - Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store? https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142 Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
Q4 Earnings Season Scorecard and Fresh Analyst Reports for Amazon, Home Depot & Merck https://www.zacks.com/commentary/2214056/q4-earnings-season-scorecard-and-fresh-analyst-reports-for-amazon-home-depot-merck?cid=CS-ZC-FT-research_daily-2214056 Jan 23, 2024 - Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152 Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026 Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now https://www.zacks.com/stock/news/2207963/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2207963 Jan 09, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024 https://www.zacks.com/stock/news/2207538/corcept-cort-stock-rises-on-upbeat-revenue-guidance-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207538 Jan 09, 2024 - Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
Merck (MRK) Advances But Underperforms Market: Key Facts https://www.zacks.com/stock/news/2207194/merck-mrk-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2207194 Jan 08, 2024 - Merck (MRK) reachead $117.38 at the closing of the latest trading day, reflecting a +0.14% change compared to its last close.
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930 Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.

Pages: 12345

<<<Page 3>